<DOC>
	<DOC>NCT01134562</DOC>
	<brief_summary>The purpose of this study is to characterize the safety and tolerability of single rising doses of KAI-4169 in hemodialysis subjects with secondary hyperparathyroidism.</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<criteria>Subjects provides written informed consent. iPTH at least 300 pg/mL (32 pmol/L) and no greater than 1200 pg/mL (127 pmol/L) and corrected calcium at least 9.0 mg/dL (2.25 mmol/L) Adequate hemodialysis three times per week Excepting chronic renal failure, subject is judged to be in stable medical condition based on medical history, physical examination, and routine laboratory tests History or symptomatic ventricular dysrhythmias History of angina pectoris or congestive heart failure History of myocardial infarction, coronary angioplasty, or coronary artery bypass grafting within the past 6 months History of or treatment for seizure disorder Recent (3 months) parathyroidectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Clinical Trial, Phase 1</keyword>
	<keyword>Renal Dialysis</keyword>
	<keyword>Secondary Hyperparathyroidism</keyword>
	<keyword>Parathyroid hormone</keyword>
</DOC>